Realm Therapeutics - Enrollment complete for Phase 2 study of PR022
Realm Therapeutics Completes Enrollment in Phase 2 Study of
PR022 for Atopic Dermatitis
Company Further Strengthens IP Portfolio with New USPTO Notice of Allowance
Reiterates Plans to File an Initial New Drug (IND) Application for
PR022 in Psoriasis in Q1'19
"This Phase 2 study is designed to demonstrate that PR022, our proprietary topical gel formulation of high concentration hypochlorous acid, has the potential to be a clinically meaningful treatment alternative for patients suffering from Atopic Dermatitis," said
The Phase 2 study is a randomized, double-blind, vehicle-controlled, multicenter, parallel-group study assessing the safety and efficacy of multiple doses of PR022 in 122 adult patients with mild-to-moderate Atopic Dermatitis. Multiple endpoints are being explored, including Eczema Area and Severity Index (EASI), an investigator-assessed tool used to measure the extent (area) and severity of atopic eczema; Investigator Global Assessment (IGA), an investigator-assessed instrument measuring severity of Atopic Dermatitis on a 5 grade scale; as well as additional assessments of pruritus and quality of life.
The Company also announces that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a new patent that expands Realm's intellectual property portfolio related to its proprietary immunomodulatory technology. U.S. Patent Application No. 15/184,207, entitled "Stabilized Hypohalous Acid Solutions," provides further coverage for composition of matter for the stabilized formulation of HOCl, for Realm's gel formulations PR022 and RLM023, as well as methods of treatment with these formulations. The patent includes specific claims for treating Atopic Dermatitis, Psoriasis and Acne.
"This additional patent allowance expands Realm's intellectual property protection for formulations based on our proprietary platform technology," continued Mr. Martin. "We believe our technology has broad-spectrum immunomodulatory effects, with potential applications in Atopic Dermatitis, Acne, Psoriasis and potentially other immune-mediated diseases. As previously announced, we plan to file two Initial New Drug (IND) applications - one for RLM023 in Acne, expected by the end of this year, and another for PR022 in Psoriasis expected in Q1 2019."
PR022 is a proprietary, non-alcohol based, topical gel formulation of high concentration HOCl, potentially offering a differentiated mechanism of action for the treatment of Atopic Dermatitis. In pre‑clinical models of Atopic Dermatitis, the Company has demonstrated that PR022 is associated with down modulation of key cytokines IL-4, IL-13 and TARC, as well as cytokines associated with itch, including IL-31 and TSLP. Importantly, these results were demonstrated without the typical immunosuppressive impact of steroids, the current standard of care, suggesting a potential clinical advantage for PR022. Realm is also evaluating PR022 for Psoriasis. Pre-clinical studies have shown in vitro and in vivo that HOCl can down modulate key cytokines TNF-α, IL-6, and IL-12, which have been reported at elevated levels in patients with Psoriasis.
RLM023 is a topical formulation of high-concentration HOCl that is being optimized for Acne. Realm believes that a HOCl based formulation may offer a promising treatment for Acne due to its anti-inflammatory and anti-microbial properties. In in vitro and in vivo pre-clinical studies, HOCl demonstrated, a reduction in the expression of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-8 and IL-12, which have been reported to be key cytokines associated with Acne pathogenesis.
About Atopic Dermatitis
Atopic Dermatitis, a serious form of eczema, is a chronic, relapsing, inflammatory disease characterized by itchy, inflamed skin, which poses a significant burden on patients' quality of life and on the overall health care system. It is most commonly first diagnosed in childhood. Patients with Atopic Dermatitis have impaired function of their skin barrier, which, combined with skin damage as a result of the intense itching and scratching associated with the disease, puts them at risk for secondary infections due to colonization with pathogenic bacteria (particularly Staphylococcus aureus) and changes in the skin microbiome. Atopic Dermatitis affects an estimated 20 million people in the U.S., including up to 20% of children and up to 3% of adults, and prevalence continues to increase.
Acne Vulgaris is the most common chronic skin condition. The disease can range from mild to severe cystic acne and is associated with significant physical and psychosocial effects on quality of life, including permanent scarring, depression and anxiety. Two of the main factors involved in the development of Acne are clogged pores and / or the presence of bacteria, leading to irritation, lesions and inflammation. Studies have demonstrated a central role of inflammation in the development of Acne lesions and have opened new opportunities for therapeutic intervention that target inflammation. Acne affects approximately 45 million people, or 14% of the population, in the U.S. Analysts value the prescription market for Acne at close to
Psoriasis is a common chronic autoimmune disorder of the skin characterized by focal formation of inflamed, raised plaques that constantly shed scales derived from excessive growth of skin epithelial cells. Research has identified key cellular and molecular pathways of inflammation that contribute to the pathogenesis of Psoriasis. Approximately 12 million people in the U.S. suffer from Psoriasis, of whom an estimated 7.5 million have been diagnosed with the skin disease, and an estimated 50% to 60% are actively being treated for the disease. Psoriasis is the largest indication in dermatology with, according to analyst estimates, approximately
About Realm Therapeutics
Realm Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics that target the interplay between innate and adaptive immunity. The Company's programs seek to influence immune signaling and change the course of immune-mediated diseases in adults and children. Realm's lead drug development program utilizes the Company's proprietary immunomodulatory technology for the treatment of Atopic Dermatitis, and the Company is exploring its efficacy in other dermatology indications which include Acne Vulgaris and Psoriasis, as well as other therapeutic areas. For more information on Realm Therapeutics please visit www.realmtx.com.
Forward Looking Statements
Certain statements made in this announcement are forward-looking statements, including with respect to the Company's clinical trials and product candidate development plans. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including clinical developments and regulatory review of product candidates. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
Outside US: +44 (0) 20 3727 1000
US: +1 212 600 1902
+1 212 600 1902
+44 (0) 20 3727 1000
N+1 Singer (Nominated Adviser and Broker)
+44 (0) 20 7496 3000
This information is provided by RNS, the news service of the